TABLE 2.
Clinical trials with PD-1/PD-L1 therapy against liver cancer.
| Cancer type | Number | Study arms (combinational) | Stage | Status | Trial NCT |
|---|---|---|---|---|---|
| HCC | 35 | Nivolumab | I | Recruiting | NCT02837029 |
| HCC | 154 | PDR001 | I | Recruiting | NCT02947165 |
| HCC | 114 | Durvalumab | I | Recruiting | NCT02572687 |
| HCC | 51 | Durvalumab | I | Recruiting | NCT02740985 |
| HCC | 75 | Nivolumab | I/II | Recruiting | NCT02423343 |
| HCC | 620 | Nivolumab | I/II | Recruiting | NCT01658878 |
| HCC | 108 | PDR001 | I/II | Recruiting | NCT02795429 |
| HCC | 50 | Prembrolizumab | I/II | Recruiting | NCT02886897 |
| HCC | 15 | Prembrolizumab | I/II | Recruiting | NCT02940496 |
| HCC | 50 | Nivolumab | I/II | Recruiting | NCT02859324 |
| HCC | 90 | Durvalumab | I/II | Recruiting | NCT02821754 |
| HCC | 620 | Nivolumab | I/II | Recruiting | NCT01658878 |
| HCC | 28 | Pembrolizumab (Keytruda) | II | Recruiting | NCT02658019 |
| HCC | 440 | Durvalumab | II | Recruiting | NCT02519348 |
| HCC | 726 | Nivolumab | III | Recruiting | NCT02576509 |
| HCC | 408 | Prembrolizumab | III | Non-recruiting; Active | NCT02702401 |
| HCC | 1,200 | Durvalumab | III | Non-recruiting | NCT03298451 |